Basic Information
Voronoi, a biotechnology company developing novel kinase inhibitors and targeted protein degraders, is collaborating on the development of innovative drugs worldwide. Voronoi covers all areas from new substance synthesis to commercialization, with its subsidiaries Voronoi Bio and B2S Bio responsible for discovering kinase inhibitor and TPD (targeted protein degrader) candidates.
Voronoi Inc.
Incheon,IncheonMetropolitanCity,SouthKorea
15~50 people
February 14, 2015
contact@voronoi.io